Hodgkin's lymphoma

ASCO: Seagen's top-selling drug under threat as Bristol Myers' Opdivo beats Adcetris in lymphoma
ASCO: Seagen's top-selling drug under threat as Bristol Myers' Opdivo beats Adcetris in lymphoma
Fierce Pharma
ASCO 2023 - Seagen
Bristol Myers Squibb
Adcetris
Opdivo
antibody-drug conjugate
Hodgkin's lymphoma
Flag link:
Seagen rolls out data for Adcetris combination to treat Hodgkin lymphoma
Seagen rolls out data for Adcetris combination to treat Hodgkin lymphoma
Endpoints
Seagen
Adcetris
ASH 2022
Hodgkin's lymphoma
Flag link:
Seagen's highest selling drug snags a label expansion for pediatric cancer patients
Seagen's highest selling drug snags a label expansion for pediatric cancer patients
Endpoints
Seagen
Takeda
Adcetris
Hodgkin's lymphoma
FDA
pediatric
Flag link:
Merck study results signal blood cancer potential for new type of immunotherapy
Merck study results signal blood cancer potential for new type of immunotherapy
BioPharma Dive
Merck
Bristol Myers Squibb
cancer
cancer immunotherapy
favezelimab
Hodgkin's lymphoma
Flag link:
FDA approves expanded indication for Merck’s KEYTRUDA in adult patients with relapsed or refractory cHL
FDA approves expanded indication for Merck’s KEYTRUDA in adult patients with relapsed or refractory cHL
Pharmaceutical Business Review
Merck
FDA
Keytruda
Hodgkin's lymphoma
Flag link:
FDA lifts partial hold on ADC, clearing way for a 2021 readout and two potential near-term approvals
FDA lifts partial hold on ADC, clearing way for a 2021 readout and two potential near-term approvals
Endpoints
ADC Therapeutics
IPOs
FDA
Cami
Hodgkin's lymphoma
Flag link:
Seattle Genetics Hits $30 Million Milestone With European Approval of Adcetris in Frontline Hodgkin Lymphoma
Seattle Genetics Hits $30 Million Milestone With European Approval of Adcetris in Frontline Hodgkin Lymphoma
CP Wire
Seattle Genetics
Adcetris
Takeda Pharmaceuticals
Hodgkin's lymphoma
Flag link:
Seattle Genetics Hits $30 Million Milestone With European Approval of Adcetris in Frontline Hodgkin Lymphoma
Seattle Genetics
Adcetris
Takeda Pharmaceuticals
Hodgkin's lymphoma
Flag link:
Number 7? Celgene partner BeiGene joins the crowd with stellar PD-1/L1 data from a pivotal test
Number 7? Celgene partner BeiGene joins the crowd with stellar PD-1/L1 data from a pivotal test
Endpoints
Celgene
BeiGene
tiselizumab
Hodgkin's lymphoma
Flag link:
Seattle Genetics Gains Another FDA Approval
Seattle Genetics Gains Another FDA Approval
BioSpace
Seattle Genetics
FDA
Adcetris
Hodgkin's lymphoma
Flag link:
ASH: Seattle Genetics CEO sees a big new Adcetris market, but one analyst has some doubts
ASH: Seattle Genetics CEO sees a big new Adcetris market, but one analyst has some doubts
Fierce Pharma
ASH17
Seattle Genetics
Adcetris
Hodgkin's lymphoma
Flag link:
ASH17: Seattle Genetics sees market opportunity in cancer combo success
ASH17: Seattle Genetics sees market opportunity in cancer combo success
BioPharma Dive
ASH17
Seattle Genetics
Adcetris
Hodgkin's lymphoma
Flag link:
Seattle Genetics Drug Scratches Out Win In Hodgkin Lymphoma
Seattle Genetics Drug Scratches Out Win In Hodgkin Lymphoma
Forbes
Seattle Genetics
Takeda
Hodgkin's lymphoma
Adcetris
Flag link:
Bristol-Myers and Seattle Genetics move a promising flagship combo into PhIII
Bristol-Myers and Seattle Genetics move a promising flagship combo into PhIII
Endpoints
Bristol-Myers
Seattle Genetics
Opdivo
Adcetris
Hodgkin's lymphoma
Flag link:
Merck's Keytruda Gets CHMP Nod for Lymphoma
Merck's Keytruda Gets CHMP Nod for Lymphoma
Investopedia
Merck
Keytruda
CHMP
Hodgkin's lymphoma
Flag link:
FDA OKs Merck’s Keytruda for Hodgkin lymphoma, a first in blood cancer
FDA OKs Merck’s Keytruda for Hodgkin lymphoma, a first in blood cancer
Endpoints
Merck
FDA
Keytruda
Hodgkin's lymphoma
Flag link:
Standing Up To The Test Of Time: Two Cancer Drugs That Could Survive A Hobbled FDA
Standing Up To The Test Of Time: Two Cancer Drugs That Could Survive A Hobbled FDA
Forbes
FDA
Seattle Genetics
Takeda
Adcetris
Hodgkin's lymphoma
AbbVie
JNJ
Ibruvica
mantle cell lymphoma
Flag link:
Seattle Genetics drug gets OK for additional cancer therapies in Europe
Seattle Genetics drug gets OK for additional cancer therapies in Europe
Bizjournals.com
Seattle Genetics
Europe
Adcetris
Hodgkin's lymphoma
Flag link:
Bristol-Myers extends lead with new Opdivo indication
Bristol-Myers extends lead with new Opdivo indication
BioPharma Dive
Bristol-Myers Squibb
Opdivo
Hodgkin's lymphoma
FDA
Flag link:
Bristol Myers Set to Enhance Dominance in Immunotherapies Market
Bristol Myers Set to Enhance Dominance in Immunotherapies Market
Bidness, ETC
Bristol-Myers Squibb
Opdivo
cancer immunotherapy
Hodgkin's lymphoma
Flag link:

Pages